[Study of the increasing effect of therapeutic efficacy of amikacin in combination with human granulocyte-colony stimulating factor (G-CSF) against experimental urinary tract infection in diabetic mice].
Clinically, prophylactic effects of Granulocyte-colony stimulating factor (G-CSF) on granulocytopenia originating from the use of anticancer agents are thought possible, and clinical studies are being performed. Recently the application of G-CSF against infectious diseases has been considered, and we reported the prophylactic effect of G-CSF against experimental urinary tract infection induced by Pseudomonas aeruginosa in diabetic mice treated Streptozotocin, a compromised host model. In this report, we investigated the therapeutic effect of G-CSF alone and in combination with Amikacin (20 mg/kg) against experimental urinary tract infection induced by Pseudomonas aeruginosa in diabetic mice. In diabetic mice, the therapeutic administration of G-CSF alone and Amikacin alone did not produce an increase of 7 day survival rate and decrease of incidence of infection. But, combinational administration of these increased the 7 day survival rate and yielded a lower incidence of infection. Thus, the therapeutic efficacy of Amikacin was improved by a combinational use of G-CSF. This result suggests that the synergy of bactericidal effect of neutrophils accelerated by G-CSF with Amikacin, and suggests the meaning and the efficacy of G-SCF as an additional therapy with antibiotics for infectious diseases.